Abivax SA Sponsored ADR $ABVX Shares Bought by Nicholas Investment Partners LP

Posted by Geri Gentry on Jun 14th, 2026

Nicholas Investment Partners LP raised its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 327.6% in the fourth quarter, HoldingsChannel reports. The fund owned 83,068 shares of the company’s stock after purchasing an additional 63,640 shares during the period. Nicholas Investment Partners LP’s holdings in Abivax were worth $11,202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. WPG Advisers LLC lifted its holdings in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after acquiring an additional 344 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the period. Union Bancaire Privee UBP SA acquired a new position in shares of Abivax during the 4th quarter worth approximately $67,000. Finally, Assetmark Inc. acquired a new position in shares of Abivax during the 4th quarter worth approximately $84,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of ABVX opened at $96.55 on Friday. Abivax SA Sponsored ADR has a one year low of $5.69 and a one year high of $148.83. The stock has a market capitalization of $7.69 billion, a price-to-earnings ratio of -18.53 and a beta of 0.69. The stock has a 50 day moving average price of $116.01 and a 200 day moving average price of $119.12.

Abivax (NASDAQ:ABVX – Get Free Report) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts predict that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Wall Street Analyst Weigh In

ABVX has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wolfe Research set a $136.00 target price on Abivax in a research note on Wednesday, June 3rd. Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and reduced their target price for the stock from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Morgan Stanley reduced their target price on Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, June 2nd. Finally, Jefferies Financial Group downgraded Abivax from a “buy” rating to a “hold” rating and reduced their target price for the stock from $160.00 to $90.00 in a research note on Tuesday, June 2nd. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and an average price target of $130.08.

Read Our Latest Analysis on ABVX

Abivax Profile

(Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.